Zydus Lifesciences (Zydus Group)

← Back to Zydus Lifesciences (Zydus Group) See how to improve →

(https://zyduslife.com) 📸 Data Snapshot: May 24, 2026

Information Density — The Lens

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Pillar: Information Density Analysis Diagnosis: Substance vs. Fluff Ratio

Info Density Power-words vs. Substance ratio.

21 Impact Weight: 30 / 100

70% Reputation

The site exhibits a dual nature: headings are saturated with power words like ‘innovation’ (used in 5 separate H2/H4 tags) and ‘breakthrough,’ while the body text provides high-density substance. Substantiated claims include the headcount of ‘29000 people,’ the ’70 years’ legacy, and specific researcher counts of ‘1500 across 19 sites.’ The ratio of fluff to specific nouns is low in the body but high in the heading hierarchy.

Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.

📝 The Narrative — clean text per page (the substance-vs-filler signal)

HOMEPAGE (https://zyduslife.com) Leading Global Pharmaceutical Company in India – Zydus group – Zydus

[H2] Over 29000 people impacting lives across the world

Zydus group is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Zydus’ global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.

Business Sites
Mfg. Sites
R & D Sites
Joint Venture

[IMG: Map]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map Pointer]

[IMG: Map]

[IMG: Map Pointer]

[IMG: Map Pointer]

[H2] Where Innovation Shapes Healthcare Solutions

Zydus’ Innovation programme is spearheaded by 1500 researchers across 19 sites, working on differentiated medicines for the future. From NCEs to vaccines, biosimilars and niche technologies, the group is exploring different ideas and concepts, innovating constantly.

[H2] Major Areas of Research

[IMG: NCE Research]
NCE Research

Cardio-Metabolic
Inflammation and Immunology,
Neurosciences, Oncology, Rare Diseases

[IMG: Biologics]
Biologics

Biosimilar Therapeutic proteins
Biosimilar Monoclonal antibodies
Biobetters and Novel biologics

[IMG: Vaccines]
Vaccines

Infectious diseases

View More

[H2] Innovation that bridges unmet healthcare needs.

[IMG: Tablets]

[H4] TwinrabTM : A Breakthrough innovation in rabies PEP

World’s First Novel Rabies Monoclonal Antibodies (mAbs) cocktail containing Docaravimab and Miromavimab, providing dual protection against rabies.

[IMG: Saroglitazar Tablets]

[H4] Lipaglyn - Novel drug to treat diabetic dyslipidemia, a global, unmet healthcare need.

The first NCE from an Indian research pipeline to move from the lab to the market.

[IMG: Adalimumab]

[H4] Exemptia - The world’s first biosimilar of Adalimumab, the largest selling therapy globally for treating auto immune disorders.

Provides a new lease of life to Indian patients of inflammatory arthritis, who did not have access to this revolutionary therapy, so far.

[IMG: VaxiFlu-4]

[H4] Vaxiflu-4 - India’s 1st Tetravalent Inactivated Influenza vaccine.

The vaccine provides protection from the four influenza viruses- H1N1, H3N2, Type B (Brisbane) and Type B (Phuket).

[H2] State-of-the-art manufacturing capabilities.

[IMG: Manufacturing]

As one of the key players amongst the pharmaceutical manufacturing companies, the group has manufacturing capabilities across the entire pharmaceutical value chain: including formulations, APIs, vaccines, biosimilars, complex products (transdermals, topical etc.), animal health products and wellness products. It has more than 30 manufacturing plants worldwide including India, Brazil and USA.

View More

3779 chars

SUB-PAGE (https://zyduslife.com/investor/) Financials, Reports & Governance – Zydus Group Investor Zone

[H2] BOARD OF DIRECTORS

[IMG: Pankaj R. Patel]

Pankaj R. Patel
Chairman

[IMG: Sharvil P. Patel]

Dr.Sharvil P. Patel
Managing Director

[IMG: Mukesh M. Patel]

Mukesh M. Patel
Director

[IMG: Humayun Dhanrajgir]

Bhadresh Shah
Director

[IMG: Akhil Monappa]

Akhil Monappa
Director

[IMG: Upasana Kamineni Konidela]

Upasana Kamineni Konidela
Director

[IMG: Shelina Parikh]

Shelina Parikh
Director

[IMG: Ganesh N. Nayak]

Ganesh N. Nayak
Director

View All

[H2] COMPOSITION OF COMMITTEES

[H2] 1

Board of Directors

[H2] 2

Audit Committee

[H2] 3

Nomination and Remuneration Committee

[H2] 4

Share Transfer Committee

[H2] 5

Stakeholders’ Relationship Committee

[H2] 6

Risk Management Committee

[H2] 7

Corporate Social Responsibility & ESG Committee

View Details

[H2] SCHEME

Voting Results of the meeting of Equity Shareholders of the Company held on March 30, 2017 pursuant to the Final Order passed by National Company Law Tribunal (“NCLT”)

Newspaper Advertisement CHL Sandesh

Newspaper Advertisement ZHL Sandesh

Newspaper Advertisement CHL Indian Express

Newspaper Advertisement ZHL Indian Express

Postal Ballot Form

Notice and Explanatory Statement CHL ES

Notice and Explanatory Statement CHL SC

Notice and Explanatory Statement CHL USC

Notice and Explanatory Statement ZHL ES

Notice and Explanatory Statement ZHL PS

Notice and Explanatory Statement ZHL SC

Notice and Explanatory Statement ZHL USC

Law Tribunal (“NCLT”)

View All

Financial Information

Schedule of analysts or institutional investors meet and presentations

Audio-Video Recordings and Transcripts

AGM

Share Holder Services

Share Holding Pattern

Press Release

[H2] Financial Information

[H4]

Notice of meeting of the Board of Directors

[H4]

2026 - 2027

[IMG: PDF Icon]
May 19, 2026

[H4]

2025 - 2026

[IMG: PDF Icon]
February 9, 2026

[IMG: PDF Icon]
November 6, 2025_03112025

[IMG: PDF Icon]
November 6, 2025

[IMG: PDF Icon]
August 12, 2025

[IMG: PDF Icon]
May 20, 2025

[H4]

2024 - 2025

[IMG: PDF Icon]
February 5 2025

[IMG: PDF Icon]
November 12 2024

[IMG: PDF Icon]
August 9 2024

[IMG: PDF Icon]
May 17 2024

[H4]

2023 - 2024

[IMG: PDF Icon]
February 9 2024 Buyback

[IMG: PDF Icon]
February 9 2024

[IMG: PDF Icon]
November 7 2023

[IMG: PDF Icon]
August 11 2023

[IMG: PDF Icon]
May 18 2023

[H4]

2022 - 2023

[IMG: PDF Icon]
February 3 2023

[IMG: PDF Icon]
Nov 11 2022

[IMG: PDF Icon]
August 10 2022

[IMG: PDF Icon]
May 20 2022

[H4]

2021 - 2022

[IMG: PDF Icon]
February 03 2022

[IMG: PDF Icon]
October 29 2021

[IMG: PDF Icon]
August 11 2021

[IMG: PDF Icon]
May 27 2021

[H4]

2020 - 2021

[IMG: PDF Icon]
February 05 2021

[IMG: PDF Icon]
November 2 2020

[IMG: PDF Icon]
August 5 2020

[IMG: PDF Icon]
June 19 2020

[H4]

2019 - 2020

[IMG: PDF Icon]
February 5 2020

[IMG: PDF Icon]
November 13 2019

[IMG: PDF Icon]
August 9 2019

[IMG: PDF Icon]
May 29 2019

[H4]

2018 - 2019

[IMG: PDF Icon]
February 7 2019

[IMG: PDF Icon]
November 3 2018

[IMG: PDF Icon]
August 13 2018

[IMG: PDF Icon]
May 25 2018

[H4]

2017 - 2018

[IMG: PDF Icon]
February 8 2018

[IMG: PDF Icon]
November 14 2017

[IMG: PDF Icon]
August 11 2017

[IMG: PDF Icon]
May 27 2017

[H4]

2016 - 2017

[IMG: PDF Icon]
March 7 2017

[IMG: PDF Icon]
January 31 2017

[IMG: PDF Icon]
October 26 2016

[IMG: PDF Icon]
August 03 2016

[IMG: PDF Icon]
May 13 2016

[H4]

2015 - 2016

[IMG: PDF Icon]
March 08 2016

[IMG: PDF Icon]
February 05 2016

[H4]

Financial Results

[H4]

2025 - 2026

[IMG: PDF Icon]
Q4 19-May-2026

[IMG: PDF Icon]
Q3 09-Feb-2026

[IMG: PDF Icon]
Q2 06-Nov-2025

[IMG: PDF Icon]
Q1 12-Aug-2025

[H4]

2024 - 2025

[IMG: PDF Icon]
Q4 20-May-2025

[IMG: PDF Icon]
Q3 05-Feb-2025

[IMG: PDF Icon]
Q2 12-Nov-2024

[IMG: PDF Icon]
Q1 09-Aug-2024

[H4]

2023 - 2024

[IMG: PDF Icon]
Q4 17-May-2024

[IMG: PDF Icon]
Q3 09-Feb-2024

[IMG: PDF Icon]
Q2 07-Nov-2023

[IMG: PDF Icon]
Q1 11-Aug-2023

[H4]

2022 - 2023

[IMG: PDF Icon]
Q4 18-May-2023

[IMG: PDF Icon]
Q3 03-Feb-2023

[IMG: PDF Icon]
Q2 11-nov-22

[IMG: PDF Icon]
Q1 10-Aug-22

[H4]

2021 - 2022

[IMG: PDF Icon]
Q4 20-May-22

[IMG: PDF Icon]
Q3 03-Feb-22

[IMG: PDF Icon]
Q2 29-Oct-21

[IMG: PDF Icon]
Q1 11-Aug-21

[H4]

2020 - 2021

[IMG: PDF Icon]
Q4 27-May-21

[IMG: PDF Icon]
Q3 05-Feb-21

[IMG: PDF Icon]
Q2 02-Nov-20

[IMG: PDF Icon]
Q1 05-Aug-20

[H4]

2019 - 2020

[IMG: PDF Icon]
Q4 19-Jun-20

[IMG: PDF Icon]
Q3 05-Feb-20

[IMG: PDF Icon]
Q2 13-Nov-19

[IMG: PDF Icon]
Q1 09-Aug-19

[H4]

2018 - 2019

[IMG: PDF Icon]
Q4 29-May-19

[IMG: PDF Icon]
Q3 07-Feb-19

[IMG: PDF Icon]
Q2 03-Nov-18

[IMG: PDF Icon]
Q1 13-Aug-18

[H4]

2017 - 2018

[IMG: PDF Icon]
Q4 25-May-18

[IMG: PDF Icon]
Q4 25-May-18 Other Information

[IMG: PDF Icon]
Q3 08-Feb-18

[IMG: PDF Icon]
Q3 08-Feb-18 Other Information

[IMG: PDF Icon]
Q2 14-Nov-17

[IMG: PDF Icon]
Q2 14-Nov-17 Other Information

[IMG: PDF Icon]
Q1 11-Aug-17 Results

[IMG: PDF Icon]
Q1 11-Aug-17 Other Information

[IMG: PDF Icon]
Q1 11-Aug-17 Limited Review Report

[H4]

2016 - 2017

[IMG: PDF Icon]
Q4 27-May-17

[IMG: PDF Icon]
Q4 27-May-17 Other Information

[IMG: PDF Icon]
Q3 31-Jan-17

[IMG: PDF Icon]
Q3 31-Jan-17 Other Information

[IMG: PDF Icon]
Q2 26-Oct-16

[IMG: PDF Icon]
Q2 26-Oct-16 Other Information

[IMG: PDF Icon]
Q1 03-Aug-16

[IMG: PDF Icon]
Q1 03-Aug-16 Other Information

[H4]

2015 - 2016

[IMG: PDF Icon]
Q4 13-May-16

[IMG: PDF Icon]
Q4 13-May-16 Other Information

[IMG: PDF Icon]
Q3 05-Feb-16

[IMG: PDF Icon]
Q3 05-Feb-16 Other Information

[IMG: PDF Icon]
Q2 22-Oct-15

[IMG: PDF Icon]
Q2 22-Oct-15 Other Information

[IMG: PDF Icon]
Q1 12-Aug-15

[IMG: PDF Icon]
Q1 12-Aug-15 Other Information

[H4]

2014 - 2015

[IMG: PDF Icon]
Q4 15-May-15

[IMG: PDF Icon]
Q4 15-May-15 Other Information

[IMG: PDF Icon]
Q3 10-Feb-15

[IMG: PDF Icon]
Q3 10-Feb-15 Other Information

[IMG: PDF Icon]
Q2 06-Nov-14

[IMG: PDF Icon]
Q2 06-Nov-14 Other Information

[IMG: PDF Icon]
Q1 30-Jul-14

[H4]

2013 - 2014

[IMG: PDF Icon]
2013-2014

[IMG: PDF Icon]
Q1 2013-14

[IMG: PDF Icon]
Q4 2013-14

[IMG: PDF Icon]
Q4 2013-14

[IMG: PDF Icon]
Q4 2013-14

[IMG: PDF Icon]
Q4 2013-14

[IMG: PDF Icon]
Q3 2013-14

[IMG: PDF Icon]
Q3 2013-14

[IMG: PDF Icon]
Q2 2013-14

[IMG: PDF Icon]
Q2 2013-14

[IMG: PDF Icon]
Q2 2013-14

[IMG: PDF Icon]
Q1 2013-14

[IMG: PDF Icon]
Q1 2013-14

[H4]

2012 - 2013

[IMG: PDF Icon]
2012-2013

[IMG: PDF Icon]
Q4 2012-13

[IMG: PDF Icon]
Q4 2012-13

[IMG: PDF Icon]
Q3 2012-13

[IMG: PDF Icon]
Q3 2012-13

[IMG: PDF Icon]
Q1 2012-13

[IMG: PDF Icon]
Q4 2012-13

[IMG: PDF Icon]
Q2 2012-13

[IMG: PDF Icon]
Q2 2012-13

[IMG: PDF Icon]
Q2 2012-13

[IMG: PDF Icon]
Q1 2012-13

[IMG: PDF Icon]
Q1 2012-13

[H4]

2011 - 2012

[IMG: PDF Icon]
2011-2012

[IMG: PDF Icon]
Q4 2011-12

[IMG: PDF Icon]
Q4 2011-12

[IMG: PDF Icon]
Q3 2011-12

[IMG: PDF Icon]
Q3 2011-12

[IMG: PDF Icon]
Q1 2011-12

[IMG: PDF Icon]
Q4 2011-12

[IMG: PDF Icon]
Q2 2011-12

[IMG: PDF Icon]
Q2 2011-12

[IMG: PDF Icon]
Q1 2011-12

[IMG: PDF Icon]
Q1 2011-12

[IMG: PDF Icon]
Q3 2011-12

[H4]

2010 - 2011

[IMG: PDF Icon]
2010-2011

[IMG: PDF Icon]
Q4 2010-11

[IMG: PDF Icon]
Q4 2010-11

[IMG: PDF Icon]
Q4 2010-11

[IMG: PDF Icon]
Q3 2010-11

[IMG: PDF Icon]
Q3 2010-11

[IMG: PDF Icon]
Q3 2010-11

[IMG: PDF Icon]
Q2 2010-11

[IMG: PDF Icon]
Q2 2010-11

[IMG: PDF Icon]
Q2 2010-11

[IMG: PDF Icon]
Q1 2010-11

[IMG: PDF Icon]
Q1 2010-11

[IMG: PDF Icon]
Q1 2010-11

[H4]

2009 - 2010

[IMG: PDF Icon]
2009-2010

[IMG: PDF Icon]
Q3 2009-10

[IMG: PDF Icon]
Q4 2009-10

[IMG: PDF Icon]
Q3 2009-10

[IMG: PDF Icon]
Q3 2009-10

[IMG: PDF Icon]
Q2 2009-10

[IMG: PDF Icon]
Q2 2009-10

[IMG: PDF Icon]
Q2 2009-10

[IMG: PDF Icon]
Q4 2009-10

[IMG: PDF Icon]
Q1 2009-10

[H4]

2008 - 2009

[IMG: PDF Icon]
2008-2009

[IMG: PDF Icon]
Q4 2008-09

[IMG: PDF Icon]
Q3 2008-09

[IMG: PDF Icon]
Q3 2008-09

[IMG: PDF Icon]
Q2 2008-09

[IMG: PDF Icon]
Q2 2008-09

[IMG: PDF Icon]
Q1 2008-09

[IMG: PDF Icon]
Q1 2008-09

[H4]

2007 - 2008

[IMG: PDF Icon]
2007-2008

[IMG: PDF Icon]
Q4 2007-08

[IMG: PDF Icon]
Q4 2007-08

[IMG: PDF Icon]
Q3 2007-08

[IMG: PDF Icon]
Q3 2007-08

[IMG: PDF Icon]
Q2 2007-08

[IMG: PDF Icon]
Q2 2007-08

[IMG: PDF Icon]
Q1 2007-08

[IMG: PDF Icon]
Q1 2007-08

[H4]

2006 - 2007

[IMG: PDF Icon]
2006-2007

[IMG: PDF Icon]
Q4 2006-07

[IMG: PDF Icon]
Q4 2006-07

[IMG: PDF Icon]
Q3 2006-07

[IMG: PDF Icon]
Q3 2006-07

[IMG: PDF Icon]
Q2 2006-07

[IMG: PDF Icon]
Q2 2006-07

[IMG: PDF Icon]
Q1 2006-07

[H4]

2005 - 2006

[IMG: PDF Icon]
2005-2006

[IMG: PDF Icon]
Q4 2005-06

[IMG: PDF Icon]
Q4 2005-06

[IMG: PDF Icon]
Q3 2005-06

[IMG: PDF Icon]
Q3 2005-06

[IMG: PDF Icon]
Q2 2005-06

[IMG: PDF Icon]
Q2 2005-06

[IMG: PDF Icon]
Q1 2005-06

[IMG: PDF Icon]
Q1 2005-06

[H4]

2004 - 2005

[IMG: PDF Icon]
2004-2005

[H4]

2003 - 2004

[IMG: PDF Icon]
2003-2004

[IMG: PDF Icon]
US-GAAP Reconciliation 2003-04

[IMG: PDF Icon]
2003-2004

[H4]

Annual Reports

[IMG: PDF Icon]
2024-2025

[IMG: PDF Icon]
2023-2024

[IMG: PDF Icon]
2022-2023

[IMG: PDF Icon]
2021-2022

[IMG: PDF Icon]
2020-2021

[IMG: PDF Icon]
2019-2020

[IMG: PDF Icon]
2018-2019

[IMG: PDF Icon]
2017-2018

[IMG: PDF Icon]
2016-2017

[IMG: PDF Icon]
2015-2016

[IMG: PDF Icon]
2014-2015

[IMG: PDF Icon]
2013-2014

[IMG: PDF Icon]
2012-2013

[IMG: PDF Icon]
2011-2012

[IMG: PDF Icon]
2010-2011

[IMG: PDF Icon]
Addendum Notice

[IMG: PDF Icon]
2009-2010

[IMG: PDF Icon]
2008-2009

[IMG: PDF Icon]
2007-2008

[IMG: PDF Icon]
2006-2007

[IMG: PDF Icon]
2005-2006 Part1

[IMG: PDF Icon]

15000 chars

🧭 Industry Context — common generic-claim patterns in Medical Devices, Pharma & Biotech to weigh the text against

Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes, pioneering medical science, the future of medicine…

Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified, patient testimonials making efficacy claims, off-label promotion signals…

Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…

Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations, specific patent numbers and status, pharmacovigilance and adverse event reporting mechanisms…

Explore the other reputation pillars for Zydus Lifesciences (Zydus Group)

Semantic Coherence → Trust & Proof → Commodity Fingerprint → Identity & Authority →

Analysis Disclosure & Source Attribution

This page presents a snapshot of public data from Zydus Lifesciences (Zydus Group), captured on May 24, 2026, to show how machine logic reads Information Density signals into an AI reputation evaluation.

Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.

Notice to Zydus Lifesciences (Zydus Group): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.

Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.

To all users: You are encouraged to visit the live site at https://zyduslife.com to view the most current version of its content and see directly what this company is about and what it offers.

Information Density: Zydus Lifesciences (Zydus Group) – Signal Evidence & AI Readability

Zydus Lifesciences (Zydus Group)